Cosmax Nbt, Inc. Overview
Cosmax NBT is the health functional food contract-development and manufacturing arm of the Cosmax Group, the world's largest cosmetics ODM. It formulates and manufactures tablets, hard and soft capsules, powders, liquids, stick jellies and gummies for brand owners, retailers, pharmaceutical and food companies, direct-selling networks and online sellers in Korea, China, the US, Australia and Southeast Asia. Its production network spans Korea (Icheon), Australia (Melbourne, TGA-certified) and, until a 2025–26 restructuring, the US (Texas). The company differentiates on formulation technology: the micro-sized tablet platform a:dam, the chewable a:dam-MINI, the melt-in-mouth BoRrr format, micro-emulsion gummies and a dedicated probiotic line. It also develops proprietary individually recognized functional ingredients such as Respecta. After four years of net losses driven by overseas start-up costs, NBT reached record quarterly revenue and operating profit in 1H FY2026. More than 70% of its sales are export-linked, which makes it a leveraged play on China, cross-border e-commerce and "K-wellness" demand.
Company's own description
In its corporate materials, Cosmax NBT describes itself as a health functional food company whose businesses are: (i) research and development of functional raw materials and ingredients; (ii) manufacturing of health functional foods and health-oriented foods; and (iii) distribution of health functional foods (Google Finance company description, sourced from company filings). Its stated vision is to become the "2030 Global No.1 health functional food company." It describes a "one-stop service" covering product proposals tailored to local markets, regulatory support in each country, and design and marketing support for clients. That service is built on what the company calls Korea's largest health functional food plant in Icheon, Gyeonggi-do, plus a US–Australia–China supply chain (company recruiting profile on Saramin). The business-purpose clause lists manufacturing, sale, import/export and mail-order sale of health functional foods and processed health beverages (JobKorea).
Independent characterization
NBT is a mid-sized, capital-intensive contract manufacturer in a fragmented Korean HFF ODM market. It has an unusually high dependence on export and China-linked demand. Its economic model has three layers:
-
ODM (Original Design Manufacturing). NBT develops the formulation and often the concept, then manufactures under the client's brand. This is the core revenue engine and earns higher gross margins than OEM because formulation IP and regulatory dossiers carry value.
-
OEM. NBT manufactures to the client's specification. The company has said the US subsidiary historically relied on OEM work, a structural reason for that unit's losses.
-
OBM (Original Brand Manufacturing). NBT supplies its own developed products and proprietary ingredients, which clients sell under their brands. Examples are individually recognized ingredients such as Respecta (women's vaginal-health probiotic) and the ashwagandha sleep ingredient, which carry pricing power and repeat-order characteristics.
Revenue model: Almost entirely product sales. In Q2 FY2026, products (manufactured goods) were 91% of revenue, merchandise (traded goods) 8% and other 1% (Butler.works, citing the 2Q26 filing). There is no subscription or licensing revenue of note. Ingredient know-how is monetized through product pricing rather than royalties.
Value-chain position: Midstream. NBT buys raw materials (vitamins, probiotics, botanical extracts, collagen, excipients and packaging), formulates, manufactures and packages finished dosage forms, and sells B2B. It does not own consumer brands at scale.
Customer types:
-
Korean brand owners and retailers. New 2026 channels named by Yuanta include convenience stores, Olive Young and Daiso.
-
Chinese brand owners selling through direct-selling (door-to-door) and cross-border e-commerce ("direct-purchase", 직구) channels.
-
US online and retail brands. The US subsidiary has been converted into a sales office supplied from Korea.
-
Australian and Southeast Asian clients served from the Melbourne plant, including the halal-certified route into Indonesia.
-
Pharmaceutical and food companies, and network-marketing companies.
End-markets: Korean HFF (estimated KRW 6.4 trillion in 2025), Chinese HFF and cross-border e-commerce, US dietary supplements, Australian complementary medicines, and emerging Indonesian (halal) and Indian demand.
Scale indicators: 32 countries and 300+ clients (Korea IR Council, 2022); "180+ clients" (company recruiting profile, undated). The company received the US$70 million Export Tower at the 62nd Trade Day in December 2025, seven years after its US$50 million tower in 2018 (Kukinews, 8 Dec 2025).
Strategy
Stated strategic themes
From company statements in press releases, award citations and the recruiting profile:
-
"2030 Global No.1 health functional food company" (corporate vision).
-
Research-centric ODM: differentiation through proprietary formulations (a:dam, a:dam-MINI, BoRrr, micro-emulsion) and individually recognized ingredients. The company describes itself as strengthening its position as an R&D-specialist company (Cosmorning, Nov 2025).
-
Global supply chain with country-specific competence: Korea, the US, Australia and China, with organic collaboration between hubs (Cosmorning, Nov 2025).
-
Digital transformation and systematization: company-wide management systems and big-data prescription automation, cited in the Presidential Commendation (Nov 2025).
-
"Snackification": described by Cosmax Group as a core trend reshaping global HFF; capacity investment in jelly, gummy and liquid-stick formats (Dailian, Jun 2026).
Initiatives in the last 24 months (Oct 2024 – Oct 2026)
| Initiative | Date | Description | Status |
|---|---|---|---|
| US manufacturing exit | 2025–2026 | First Texas plant sold (US$14.25M); second sale planned for 2026; US entity converted to a sales office supplied from Korea | First sale completed; second pending (a subsidiary asset-disposal decision was filed 28 Jul 2026) |
| Australia recapitalization | Sep 2024; Jul 2026 | KRW 3.6bn and KRW 10.4bn share subscriptions to restore equity and "secure production capability" | Completed; 100% owned |
| Cosmax NS absorption | Mar–Jun 2026 | KRW 3.8bn buy-in of remaining shares, then a small-scale, no-new-share merger (ratio 1:0) | Completed 30 Jun 2026; registration 3 Jul 2026 |
| Snack-format capacity | 1H 2026 | Stick-jelly line upgraded from 5-row to 12-row filler; monthly capacity roughly doubled from 15M sachets; gummy forming/filling equipment added | Completed |
| New domestic channels | 2,026 | Supply to convenience stores, Olive Young and Daiso private-label / brand partners | Contributing (Yuanta, Sep 2026) |
| Halal / Indonesia | 2024 onward | MUI halal certification via the Australian plant; inner-beauty HFF with Cosmax Indonesia | — |
| India | 2024 onward | Ashwagandha-based collaboration; OBM functional coffee | Pipeline |
| Trade shows | Jun 2026 | HNC 2026 (Shanghai, 15–17 Jun) with Cosmax Bio: snack formats, a:dam, PDRN | Completed |
| K-beauty crossover | 2,026 | Yuanta flags potential ODM/OEM collaboration with K-beauty companies on inner-beauty products | Prospective |
| Tax recovery | 2Q 2026 | KRW 25.7bn corporate-tax refund from a correction claim | Recognized in 2Q26 |
Medium-term financial targets
| Metric | FY2025 | FY2026F | FY2027F |
|---|---|---|---|
| Operating income (KRW bn) | 4.0 | 35.9 | 42.3 |
| Net income (KRW bn) | -15.0 | 21.0 | 26.0 |
Management has not publicly disclosed numeric medium-term targets or formal guidance in the sources reviewed. The quantitative framework below comes from sell-side forecasts.
Sources: DS Investment & Securities. Operating income forecasts are from 10 Aug 2026; net income forecasts are from 8 May 2026 (before the 2Q26 tax refund, which will raise the FY2026 figure). DS's implied FY2026 revenue is about KRW 399bn (1H actual KRW 195.5bn plus 2H forecast KRW 203.5bn).
ESG and sustainability commitments
No company-specific emissions targets or sustainability-linked financing were identified.
Products & Services
Prices are not publicly disclosed; B2B pricing is negotiated per project. Launch years are given where verifiable.
Dosage-form platforms (manufacturing capabilities)
| Platform | Description / capability | Target customers | Year / status | Source |
|---|---|---|---|---|
| Tablets (conventional) | Compressed tablets, coated and uncoated | Brand owners, pharma, network marketing | Legacy core | Korea IR Council, 2022 |
| Hard capsules | Powder-fill hard capsules | Brand owners | Legacy core | Hi Investment, 2021 |
| Soft capsules | Oil-based actives (e.g., krill oil, omega-3) | Brand owners; online / home-shopping channels | Legacy core | eBest, Aug 2020 (krill oil demand) |
| Powders / sticks | Powder sachets and sticks; a historical strength | Probiotic and collagen brands | Legacy core | Korea IR Council, 2022 |
| Liquids | Drinkable ampoules and liquid shots; another historical strength | Beauty-from-within and energy brands | Legacy core | Korea IR Council, 2022 |
| Stick jelly (back-seal sticks) | Jelly/gel sachets; 12-row filling line added in 1H26 alongside the older 5-row line, roughly doubling monthly capacity from 15M sachets | "Snackification" brands; export clients | Upgraded 2026 | Dailian; Cosinkorea, Jun 2026 |
| Gummies | Molded gummies with new forming and filling equipment; micro-emulsion technology improves stability of fat-soluble actives | Convenience-store, Olive Young and Daiso channels; export | Expanded 2026 | Cosinkorea, Jun 2026; Yuanta, Sep 2026 |
| Dedicated probiotic line (EPP) | Described as the industry's first dedicated probiotic production line | Probiotic brands | Operating | Company profile (Saramin) |
| Multipacks | Multi-supplement daily packs; sales up about 85% in 2023 | Personalized-nutrition and subscription brands | Growing | Cosmorning |
Proprietary formulation technologies
| Technology | Specification | Target use | Year | Source |
|---|---|---|---|---|
| a:dam™ (아담) | Micro-sized tablet; proprietary process cuts non-functional excipient by up to 87% and tablet size by up to 66% while keeping active content and stability | Multipacks, older consumers, pill-fatigue segments | Shown HNC 2024; AAES award 2024 | Cosmorning |
| a:dam™-MINI | Crunchy micro-tablet chewed without water; about 0.35 cm per piece | Children, seniors | Launched 2024 | Cosmorning |
| BoRrr (보르르) | Fast-melting format that dissolves easily in the mouth | Convenience-focused consumers | Cited 2025 | Cosmorning, Nov 2025 |
| Micro-emulsion | Emulsification technology for gummies and jellies with improved bioavailability and stability | Gummy/jelly ODM | Cited 2026 | Yuanta, Sep 2026; company profile |
| Digital prescription automation | Big-data-based formulation/prescription automation system | Internal R&D productivity | Cited Dec 2025 | Kukinews, Dec 2025 |
Proprietary ingredients and branded actives (OBM)
| Ingredient / product | Function | Status | Source |
|---|---|---|---|
| Respecta (리스펙타) | Women's vaginal-health probiotic (individually recognized functional ingredient) | Sales about KRW 6bn in 1Q21, roughly double the 2020 quarterly average | IBK, May 2021 |
| Collagen products | Skin health; distribution expanded in 2021 | Ongoing | IBK, May 2021 |
| Ashwagandha (sleep) | Individually recognized by Korea's MFDS for sleep function; basis for India collaboration | Approved; India OBM planned | Dealsite, Mar 2024 |
| Joint-health ingredient | Individually recognized ingredient | Launched 2Q22 | IBK, Apr 2022 |
| Skin-health ingredient | Individually recognized ingredient | Launched 2021 | IBK, May 2021 |
| Functional coffee (OBM) | Planned product for India | Pipeline | Dealsite, Mar 2024 |
| PDRN material | Shown with Cosmax Bio at HNC 2026 | Commercialization stage not disclosed | Cosinkorea, Jun 2026 |
| Inner-beauty HFF for Indonesia | Skin improvement and body-fat reduction, developed with Cosmax Indonesia's halal know-how | Planned | Dealsite, Mar 2024 |
Services
Regulatory affairs: country-specific registration support (Korea MFDS, Australia TGA, US NSF-certified manufacturing, Indonesia MUI halal).
Design and marketing support: packaging design and launch support for clients.
Certifications held: NSF, TGA, K-GMP, ISO 22000, HALAL, HACCP (company profile, Saramin).
Financial Narrative
All figures: K-IFRS consolidated, KRW millions, fiscal years ending 31 December. Source: S&P Global Market Intelligence via StockAnalysis.com, unless stated otherwise.
Income statement
Cross-check: Butler.works (FnGuide-type data) reports operating income of KRW 6.4bn / 2.2bn / 12.0bn / 9.9bn / 4.0bn and net income of KRW -5.3bn / -12.9bn / -5.8bn / -5.4bn / -15.1bn for FY2021–FY2025. The small net-income gaps reflect consolidated versus controlling-interest presentation.
Margins and growth
Revenue CAGR FY2021–FY2025: -0.2% a year (analyst calculation: 287,479 / 289,347 over four years).
Quarterly bridge (FY2025 → 1H FY2026)
Sources: Kormedi (2Q26 and 1H26/1H25 preliminary figures); Herald Economy (1Q26); Google Finance (3Q25 and 4Q25 revenue); DS Investment (quarterly OI). 1Q25 revenue and net income are derived by subtracting 2Q25 from the 1H25 totals (1H25 revenue KRW 147.83bn, OI KRW 3.39bn, net loss KRW 3.42bn). The 2Q26 net income includes a KRW 25.7bn corporate-tax refund from a correction claim (경정청구) (DS Investment, 10 Aug 2026).
1H FY2026 vs 1H FY2025: revenue KRW 195.53bn vs 147.83bn (+32.3%); operating income KRW 18.75bn vs 3.39bn (+452.8%); net income KRW 39.46bn vs -3.42bn.
Balance sheet
Interim position, 30 June 2026 (S&P): total assets KRW 334.6bn; cash KRW 52.7bn; short-term borrowings KRW 156.7bn; current LT debt KRW 2.5bn; long-term debt nil; total debt KRW 161.3bn; net debt KRW 108.6bn; equity KRW 92.4bn (minority interest removed after the subsidiary mergers and buy-ins); working capital KRW -40.1bn; book value per share KRW 4,494.
The FY2024 increase in equity from KRW 40.6bn to KRW 62.0bn came mainly from other comprehensive income, which rose from KRW 2.3bn to KRW 29.4bn.
Cash flow
The FY2025 "other investing" inflow of KRW 20.6bn matches the US$14.25M first US plant sale (about KRW 20bn at prevailing exchange rates). The company said these proceeds would go toward debt repayment (Herald Economy, May 2026). Trailing twelve months to June 2026: OCF KRW 31.0bn, capex KRW 12.6bn, FCF KRW 18.4bn, net debt repaid KRW 40.9bn (S&P).
Ratios (analyst calculations from the S&P data above)
At 30 June 2026, debt/equity had improved to 1.75x and the current ratio to 0.82x. S&P reports TTM interest coverage of 1.42x (at end-March 2026), an Altman Z-score of 0.96 and a Piotroski F-score of 5.
Commentary: trends, inflections and drivers
Revenue (FY2021–FY2025). Revenue peaked at KRW 333.6bn in FY2023, then fell two years running to KRW 287.5bn in FY2025, below the FY2021 level. The FY2025 shortfall was severe against expectations: in February 2025, DS Investment had forecast FY2025 revenue of KRW 350.8bn (+10%) and operating profit of KRW 20.9bn. Actual results were 18% and 81% lower. The drivers named by brokers and the company were:
-
a high base from a major client's new-product launches in 2024;
-
order gaps at existing customers;
-
the halt of US production as plants were sold, which removed US manufacturing revenue (Herald Economy, May 2026);
-
provisioning and one-off disposal costs.
Gross margin. Gross margin held in a narrow 11.6–14.5% band. It reflects heavy fixed costs: PP&E of more than KRW 100bn against sales of about KRW 300bn, and under-utilized overseas plants. The FY2022 trough (11.6%) coincided with the US two-plant structure running below capacity. The jump to 20.0% in 1Q26 (COGS KRW 74.6bn on revenue KRW 93.3bn, per Google Finance) shows the operating leverage once US fixed costs were removed and Korean volumes rose.
Operating to net income. Net losses occurred in every year despite positive operating profit. Two items explain the gap: (i) interest expense of KRW 10–12bn a year since FY2023, on short-term borrowings rolled at higher Korean rates; and (ii) tax expense structurally above pre-tax income. Profitable Korean operations paid tax while overseas losses produced no deferred-tax benefit, so effective rates exceeded 1,000% in FY2023–FY2024. FY2025 also included KRW 3.8bn of asset-disposal losses and KRW 4.0bn of write-downs.
Balance sheet. Funding is almost entirely short-term. Short-term borrowings of KRW 156.7bn are about 97% of total debt at 30 June 2026, so the company depends on annual bank rollovers. Working capital was negative throughout, and S&P's current ratio of 0.68 (TTM) and Z-score below 1 flag elevated financial risk on paper. Deleveraging since FY2024 is real: total debt fell from KRW 203.9bn (FY2023) to KRW 161.3bn (Jun 2026), helped by the US asset sale, positive FCF and the 2Q26 tax refund. The second US plant sale (proceeds again earmarked for debt reduction) and 2H26 earnings are the next steps.
Cash generation. FCF turned consistently positive from FY2024 (KRW 4.8bn) to FY2025 (KRW 9.4bn) and TTM June 2026 (KRW 18.4bn). Capex has stayed modest (KRW 4–18bn), concentrated on Korean formulation lines (stick jelly, gummies) rather than new plants.
Inflection. 1H FY2026 marks a clear break. Quarterly operating margins of 8–11% compare with a 0.7–3.6% annual range in FY2021–FY2025. If 2H26 delivers the KRW 17.1bn operating profit DS forecasts, FY2026 operating income of about KRW 36bn would be roughly three times the previous record (FY2023: KRW 12.0bn).
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Group Entities
| Entity | Country | Function | Status (Oct 2026) |
|---|---|---|---|
Cosmax NBT, Inc. (parent, "Korea standalone") | Korea | HQ, R&D, Icheon manufacturing, export hub | Core profit center |
Cosmax NS (formerly Nutri Science) | Korea | Functional ingredient / materials subsidiary | Absorbed into parent, 30 Jun 2026 |
Cosmax NBT USA | US (Dallas, Texas) | Formerly manufacturing; now a sales-centric entity supplied from Korea | First plant sold 2025; second sale planned for 2026 |
Cosmax NBT Australia Pty Ltd | Australia (Melbourne) | TGA-certified manufacturing; China, Australia and halal/SEA exports | 100% owned; recapitalized 2024 and 2026 |
Cosmax NBT Shanghai | China | Sales subsidiary | Operating (scale not separately disclosed recently) |
Group Entities (FY2021)
| Entity (share of pre-elimination revenue, %) | FY2021 |
|---|---|
Korea standalone (%) | 62.2 |
US subsidiary (%) | 11.4 |
Australia subsidiary (%) | 10.0 |
Shanghai subsidiary (%) | 10.7 |
Cosmax NS (%) | 5.7 |
Revenue by Segment
| Metric | FY2024 | FY2025 |
|---|---|---|
US subsidiary revenue (KRW Bn) | 21.7 | 22.0 |
US subsidiary operating income (KRW Bn) | -17.0 | -7.8 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansRevenue by Segment (FY2022–FY2023)
| Metric | FY2022 | FY2023 |
|---|---|---|
Australia subsidiary revenue (KRW Bn) | 57.0 | 74.7 |
Revenue by Segment (FY2025)
| Metric | FY2025 |
|---|---|
Korea standalone revenue (KRW Bn) | 206.9 |
Segment Revenue
| Metric | 1Q25 | 2Q25 | 3Q25 | 4Q25 | 1Q26 | 2Q26 |
|---|---|---|---|---|---|---|
US subsidiary revenue (KRW Bn) | 5.6 | 8.5 | 4.0 | 3.9 | 3.5 | 4.9 |
US subsidiary operating income (KRW Bn) | -3.6 | -1.0 | -2.0 | -1.2 | -0.2 | — |
Income Statement and Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue (KRW Mn) | 289,347 | 328,207 | 333,631 | 317,985 | 287,479 |
Revenue growth (%) | 8.46 | 13.43 | 1.65 | -4.69 | -9.59 |
Cost of revenue (KRW Mn) | 251,619 | 290,235 | 285,300 | 273,954 | 246,817 |
Gross profit (KRW Mn) | 37,728 | 37,973 | 48,330 | 44,031 | 40,662 |
SG&A (KRW Mn) | 27,393 | 32,901 | 33,723 | 29,877 | 32,891 |
Operating income (KRW Mn) | 6,434 | 2,240 | 11,977 | 9,905 | 4,003 |
D&A (KRW Mn) | 15,581 | 15,814 | 13,543 | 14,161 | 12,485 |
EBITDA (KRW Mn) | 22,015 | 18,054 | 25,520 | 24,066 | 16,488 |
Interest expense (KRW Mn) | 5,282 | 7,817 | 11,701 | 11,575 | 10,013 |
Pre-tax income (KRW Mn) | 2,308 | -4,543 | 409 | 405 | -13,822 |
Income tax expense (KRW Mn) | 7,649 | 8,372 | 6,238 | 5,853 | 1,257 |
Net income attributable to owners (KRW Mn) | -6,393 | -13,070 | -6,493 | -5,754 | -15,037 |
EPS basic (KRW) | -309.93 | -633.61 | -314.76 | -279.00 | -731.57 |
EPS diluted (KRW) | -309.93 | -633.61 | -314.76 | -279.00 | -731.57 |
Dividends per share (KRW) | 0 | 0 | 0 | 0 | 0 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansMargin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Gross margin (%) | 13.04 | 11.57 | 14.49 | 13.85 | 14.14 |
Operating margin (%) | 2.22 | 0.68 | 3.59 | 3.12 | 1.39 |
EBITDA margin (%) | 7.61 | 5.50 | 7.65 | 7.57 | 5.73 |
Net margin (%) | -2.21 | -3.98 | -1.95 | -1.81 | -5.23 |
Financial Analysis
| Metric | 1Q25 | 2Q25 | 3Q25 | 4Q25 | 1Q26 | 2Q26 |
|---|---|---|---|---|---|---|
Revenue (KRW Bn) | 72.2 | 75.7 | 65.7 | 74.0 | 93.3 | 102.3 |
Operating income (KRW Bn) | 0.9 | 2.5 | -1.2 | 1.8 | 10.3 | 8.5 |
Operating margin (%) | 1.2 | 3.3 | -1.8 | 2.4 | 11.0 | 8.3 |
Net income (KRW Bn) | -2.3 | -1.1 | — | — | 9.1 | 30.3 |
Balance Sheet and Per-Share Data
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Total assets (KRW Mn) | 310,464 | 303,971 | 300,078 | 317,246 | 282,959 |
Cash & equivalents (KRW Mn) | 56,482 | 63,885 | 59,529 | 45,267 | 48,322 |
Accounts receivable (KRW Mn) | 42,879 | 42,897 | 48,250 | 48,070 | 41,209 |
Inventory (KRW Mn) | 49,532 | 42,866 | 35,459 | 37,670 | 39,433 |
Total current assets (KRW Mn) | 156,616 | 159,271 | 151,659 | 144,400 | 136,164 |
PP&E (KRW Mn) | 146,717 | 108,329 | 112,368 | 133,328 | 104,109 |
Goodwill & intangibles (KRW Mn) | 1,300 | 904 | 778 | 1,047 | 764 |
Short-term borrowings (KRW Mn) | 129,806 | 144,137 | 150,054 | 170,199 | 159,156 |
Current portion of LT debt (KRW Mn) | 25,918 | 24,975 | 36,000 | 18,533 | 4,167 |
Long-term debt (KRW Mn) | 45,912 | 36,500 | 13,394 | 1,667 | 1,250 |
Lease liabilities, total (KRW Mn) | 2,184 | 2,191 | 4,444 | 3,269 | 2,912 |
Total debt incl. leases (KRW Mn) | 203,819 | 207,803 | 203,892 | 193,668 | 167,484 |
Net debt (KRW Mn) | 147,336 | 143,918 | 144,362 | 148,401 | 119,162 |
Total current liabilities (KRW Mn) | 198,120 | 212,093 | 233,628 | 237,166 | 214,951 |
Total liabilities (KRW Mn) | 252,048 | 256,717 | 259,487 | 255,244 | 234,117 |
Equity attributable to owners (KRW Mn) | 55,358 | 43,513 | 36,205 | 57,343 | 44,228 |
Total equity (KRW Mn) | 58,416 | 47,254 | 40,591 | 62,002 | 48,842 |
Working capital (KRW Mn) | -41,505 | -52,822 | -81,969 | -92,766 | -78,787 |
Book value per share (KRW) | 2,683.61 | 2,109.42 | 1,761.40 | 2,789.76 | 2,151.69 |
Cash Flow
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Operating cash flow (KRW Mn) | -8,190 | 13,612 | 16,780 | 9,114 | 18,263 |
Capital expenditure (KRW Mn) | -4,746 | -6,006 | -17,383 | -4,317 | -8,843 |
Free cash flow (KRW Mn) | -12,936 | 7,606 | -603 | 4,797 | 9,421 |
Proceeds from PP&E sales (KRW Mn) | 1,862 | 3,635 | 3,670 | 47 | 690 |
Other investing inflows (KRW Mn) | 608 | 916 | 546 | 28 | 20,607 |
Dividends paid (KRW Mn) | 0 | 0 | 0 | 0 | 0 |
Share buybacks (KRW Mn) | 0 | 0 | 522 | 0 | 0 |
Net debt issued / repaid (KRW Mn) | 394 | -5,439 | -7,665 | -19,887 | -28,850 |
Cash interest paid (KRW Mn) | 5,283 | 7,354 | 13,739 | 11,684 | 10,371 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
ROE on year-end owners' equity (%) | -11.55 | -30.04 | -17.93 | -10.03 | -34.00 |
ROA on year-end assets (%) | -2.06 | -4.30 | -2.16 | -1.81 | -5.31 |
Pre-tax ROIC, EBIT / (net debt + equity) (%) | 3.13 | 1.17 | 6.48 | 4.71 | 2.38 |
Current ratio (x) | 0.79 | 0.75 | 0.65 | 0.61 | 0.63 |
Debt / equity (x) | 3.49 | 4.40 | 5.02 | 3.12 | 3.43 |
Net debt / EBITDA (x) | 6.69 | 7.97 | 5.66 | 6.17 | 7.23 |
Interest coverage, EBIT / interest (x) | 1.22 | 0.29 | 1.02 | 0.86 | 0.40 |
Asset turnover (x) | 0.93 | 1.08 | 1.11 | 1.00 | 1.02 |
Days sales outstanding (days) | 54.1 | 47.7 | 52.8 | 55.2 | 52.3 |
Days inventory outstanding (days) | 71.9 | 53.9 | 45.4 | 50.2 | 58.3 |
Days payables outstanding (days) | 36.6 | 26.3 | 34.3 | 38.0 | 41.8 |
Cash conversion cycle (days) | 89.4 | 75.3 | 63.9 | 67.4 | 68.8 |
Revenue by Region (%) and Revenue by Region
| Metric | FY2022 | FY2024 | FY2025 |
|---|---|---|---|
Overseas share of revenue (%) | 62 | 70 | 70 |
Domestic share of revenue (%) | 38 | 30 | 30 |
Implied overseas revenue (KRW Bn) | 203.5 | 222.6 | 201.2 |
Implied domestic revenue (KRW Bn) | 124.7 | 95.4 | 86.2 |
Share Price History
| Date | Price (KRW) | Source |
|---|---|---|
4 Aug 2020 | 9,390 | Hana Financial Investment |
7 Jun 2021 | 11,450 | Kiwoom Securities |
24 Feb 2025 | 3,360 | DS Investment |
7 May 2026 | 5,230 | DS Investment |
24 Jul 2026 | 7,470 | StockAnalysis |
7 Aug 2026 | 8,630 | DS Investment; Kormedi |
10 Aug 2026 | 10,700 | StockAnalysis (+23.99% on the day) |
21 Aug 2026 | 8,060 | StockAnalysis |
15 Sep 2026 | 7,380 | Google Finance |
Latest snapshot (undated, Sep–Oct 2026) | 8,310 | Butler.works |
Valuation Multiples
| Multiple | Cosmax NBT | Basis / source |
|---|---|---|
Market cap (KRW Bn) | 171.4 | Butler.works at KRW 8,310 |
Enterprise value (KRW Bn) | About 280 | Market cap plus Jun-26 net debt of KRW 108.6bn (analyst) |
P/E (TTM) | 6.15 | Butler.works; TTM net income KRW 27.9bn includes the KRW 25.7bn tax refund |
P/E (forward) | 4.64 | Butler.works |
EV/EBITDA (TTM Jun-26) | About 9.3 | EV KRW 280bn / TTM EBITDA about KRW 30.1bn (analyst) |
EV/Sales (TTM Jun-26) | About 0.84 | EV / TTM revenue KRW 335.2bn (analyst) |
P/B | 1.85 | Butler.works; equity KRW 92.4bn |
Beta (5Y) | 0.92 | S&P |
Analyst Ratings & Targets
| Broker | Date | Rating | Target price (KRW) |
|---|---|---|---|
DS Investment & Securities | 25 Feb 2025 | Buy | 6,000 |
DS Investment & Securities | 8 May 2026 | Buy | 10,000 |
DS Investment & Securities | 10 Aug 2026 | Buy | 12,000 |
Hana Securities | 8 Jul 2026 | Not rated (preview) | — |
Yuanta Securities Korea | 7 Sep 2026 | No rating | — |
Consensus (3 brokers) | Latest | — | 12,000 |
Analyst Conclusions
Guidance and consensus
Management guidance: none published in quantitative form. Qualitatively, management highlights new domestic channels, export growth to China, the US and Southeast Asia, snack-format capacity and formulation technology.
Sell-side (DS, Aug 2026): - 2H26 revenue KRW 203.5bn (+46% YoY) and OI KRW 17.1bn.
-
FY2026 OI KRW 35.9bn; implied FY2026 revenue about KRW 399bn (+39%).
-
FY2027 OI KRW 42.3bn (+18%).
Next catalyst: 3Q26 preliminary results, expected in early-to-mid November 2026 (the 3Q25 results were filed 7 Nov 2025). DS's 3Q26 OI forecast was KRW 9.0bn (May 2026 version: KRW 7.9bn).
Bull case
-
Structural margin reset: removing US manufacturing fixed costs plus Korean operating leverage lifted gross margin to 17.6–20.0% in 1H26 (vs 14.1% in FY2025). A sustained 8–10% operating margin on about KRW 400bn of revenue supports the KRW 36–42bn OI trajectory.
-
Deleveraging flywheel: the US plant proceeds (US$14.25M already, more pending), the KRW 25.7bn tax refund and TTM FCF of KRW 18.4bn have already cut debt/equity from 3.43x to 1.75x in six months. Each KRW 10bn of debt repaid saves roughly KRW 0.5–0.6bn of interest a year (analyst estimate at prevailing rates).
-
Channel diversification: new retail channels (convenience stores, Olive Young, Daiso) and K-beauty inner-beauty crossover reduce reliance on China direct-selling, while snack-format capacity has doubled.
Bear case
-
Earnings quality and credibility: 2Q26 net income of KRW 30.3bn is about 85% one-off (the tax refund). The FY2025 miss against forecasts (OI KRW 4.0bn vs KRW 20.9bn expected) shows how quickly a concentrated client base can erode earnings.
-
China dependence: the company remains among the most China-exposed Korean consumer stocks. A repeat of the 2022 direct-selling slump would hit both the Korean and Australian plants.
-
Balance-sheet fragility persists: about 99% of debt is due within 12 months, the current ratio is 0.82x, and S&P's Altman Z-score is 0.96. A credit squeeze or a weak quarter could force further affiliate support, and minority shareholders are already litigating governance issues.
Catalysts and monitorables (next 12 months)
-
3Q26 and 4Q26 results: whether operating margin holds above 8% without one-offs.
-
Completion and pricing of the second US plant sale (the 28 Jul 2026 asset-disposal filing).
-
Australian subsidiary profitability after the KRW 10.4bn July 2026 recapitalization.
-
FY2026 Annual Business Report (around March 2027): net debt, refinancing terms, any dividend-policy statement.
-
Progress of minority-shareholder litigation and any change in auditor or board composition.
-
Halal (MUI) certification and first Indonesian or Indian commercial orders.
-
Cosmax BTI governance after the September 2026 leadership change.
-
KRW/USD and KRW/CNY moves, and US tariff policy on Korean-made supplements.
Analyst verdict
Cosmax NBT is a classic restructuring-to-recovery story that has moved from thesis to evidence in 2026. For most of the past decade the company was a reasonable Korean HFF manufacturer weighed down by an overseas footprint it could not fill. Texas and Melbourne plants built ahead of demand produced years of losses, negative subsidiary equity, KRW 10–12bn of annual interest expense and five straight years of net losses. Management's response has been decisive: consolidate and then sell the US plants, turn the US into a sales office supplied from Korea, recapitalize Australia, absorb Cosmax NS, and concentrate investment on high-velocity Korean formulation lines. The results are visible. Quarterly operating margins of 8–11% in 1H26 compare with a five-year annual peak of 3.6%, and debt/equity has halved in six months.
The investment debate now turns on durability, not direction. Normalized earnings are smaller than headline TTM P/E suggests because the 2Q26 tax refund flatters net income, and growth still depends heavily on China-linked and newly won domestic retail clients whose order patterns have proven volatile. The capital structure, nearly all short-term bank debt, leaves little room for a stumble, and governance friction with minority investors is an overhang that the controlling group has not resolved transparently.
On balance, at about KRW 8,300 (EV about KRW 280bn, about 9x TTM EV/EBITDA and about 7–8x DS's FY2026 OI), the market has priced in a good share of the turnaround. The KRW 12,000 consensus target implies further upside only if 2H26 confirms DS's KRW 17bn operating profit forecast without one-offs. We would characterize the shares as a high-beta, catalyst-driven recovery position. The upside requires continued quarterly execution and visible deleveraging. Investors should size positions with the company's financial fragility and forecasting history in mind, and treat the 3Q26 print as the key test.
End of dossier. All figures are in KRW unless otherwise stated.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Title | Tenure | Prior roles / notes |
|---|---|---|---|
Kim Nam-joong (김남중) | CEO / Representative Director | Since Mar 2025 | Cosmax production head (EVP-level, promoted Jan 2021); promoted to vice-president and named NBT CEO-designate Dec 2024; Minister of Trade, Industry and Energy commendation, Dec 2025 |
Park Jong-cheol (박종철) | Head of Production; promoted to Managing Director (상무) | Promoted Dec 2024 | Production division |
Kim Ui-taek (김의택) | Managing Director (상무) | Promoted effective 1 Jan 2026 | — |
Lee Su-yeon (이수연) | Junior Managing Director (상무보) | Appointed effective 1 Jan 2026 | — |
Major Shareholders
| Holder | Stake | Source / date |
|---|---|---|
Cosmax BTI, Inc. (direct) | 43.53–43.68% | Herald Economy, May 2026; Cosmax BTI disclosures (etfshopping) |
Cosmax BTI plus 11 related parties | 44.0% (Aug 2026); 44.5% (May 2026) | DS Investment |
Treasury stock (incl. related) | 0.4% | DS Investment |
Foreign investors | 5.3% (Aug 2026), up from 1.25% (May 2026) | DS Investment |
Insiders (per S&P definition) | 0.45% | S&P / StockAnalysis |
Free float | About 11.48M shares (~56%) | S&P / StockAnalysis |
Competitive Landscape
Key Competitors
| Competitor | Listing | Positioning | FY2025 revenue (KRW Bn) | FY2025 OI (KRW Bn) | Notes | Source |
|---|---|---|---|---|---|---|
Kolmar BNH | KOSDAQ: 200130 | Largest Korean HFF ODM by revenue; Atomy-linked; Haleon partnership | 574.9 | 26.6 | FY2025 net loss KRW 22.6bn; Chinese subsidiary in negative equity | Butler.works; Dealsite |
Novarex | KOSDAQ: 194700 | No.1 Korean HFF ODM by capacity; 49 individually recognized ingredients | 404.3 | 43.1 (10.65% OPM) | ROE about 15%; FY26E P/E about 6.2x | AlphaDistill |
Seoheung | KOSPI: 008490 | No.1 Korean hard-capsule maker; HFF OEM | — | — | Trailing P/E about 5.2x | AlphaDistill |
Cosmax Bio | Unlisted (Cosmax BTI subsidiary) | Sister HFF ODM; stick jelly, liquid sticks | — | — | Exports US$5.41M (Jul 2024–Jun 2025) | Kukinews |
Chong Kun Dang Bio | KOSDAQ | Probiotic ingredients (supplier to the "Lactofit" brand) | — | — | Ingredient competitor | Hankyung Business, 2020 |
Nutri (뉴트리) | KOSDAQ | Brand / ODM | — | — | Loss-making or break-even in 2025 | AlphaDistill |
HL Science | KOSDAQ | Ingredients / brand | — | — | Loss-making or break-even in 2025 | AlphaDistill |
Frombio | KOSDAQ | Ingredients / ODM | — | — | Loss-making or break-even in 2025 | AlphaDistill |
Natural Way | Private | HFF OEM/ODM | — | — | Named peer | TheVC |
Kwangdong Health Bio | Private | HFF OEM/ODM | — | — | Named peer | TheVC |
Huons N | Private / affiliate | HFF | — | — | Named peer | TheVC |
“—” = not publicly disclosed.
Peer Comparison FY2025
| Metric | Cosmax NBT | Kolmar BNH | Novarex |
|---|---|---|---|
Revenue (KRW Bn) | 287.5 | 574.9 | 404.3 |
Revenue growth (%) | -9.6 | -6.6 | — |
Operating margin (%) | 1.4 | 4.6 | 10.65 |
Net income (KRW Bn) | -15.0 | -22.6 | — |



